TWiV 899: COVID-19 clinical update #114 with Dr. Daniel Griffin
b'
In COVID-19 clinical update #114, Dr. Griffin discusses early treatment with ivermectin, procalcitonin not a reliable biomarker, vaccine in 6-11 year olds, FDA limits use of Janssen vaccine, does site of vaccine booster matter, sniffer dogs, monoclonals for hospitalized patients, risk assessment for public events, Paxlovid eligibility, and persistence of pediatric anosmia.
Subscribe (free):\\xa0Apple Podcasts,\\xa0Google Podcasts,\\xa0RSS,\\xa0email
Become a\\xa0patron\\xa0of\\xa0TWiV!
Links for this episode
- Effects\\xa0of early treatment with Ivermectin (NEJM)
- Procalcitonin not a\\xa0reliable biomarker\\xa0(IDSA)
- Evaluation of vaccine\\xa0in children 6 to 11 years (NEJM))
- FDA\\xa0limits use of Janssen\\xa0vaccine (FDA)
- Recall of b cell memory\\xa0on vaccination location (Science Immunology)
- Persistence screening using\\xa0sniffer dogs\\xa0(Journal of Clinical Trials)
- Tixagevimab/Cilgavimab for treatment\\xa0of hospitalized patients (Lancet)
- Infection detection by\\xa0canine olfaction\\xa0(OFID)
- Diagnostic utility\\xa0to differentiate patients (IDSA)
- Prevalence of\\xa0anosmia in pediatric cases\\xa0(Pediatric Infectious Disease Journal)
- Risk assessment\\xa0for public events (University of Texas COVID-19 Modeling Consortium)
- PAXLOVID patient eligibility\\xa0screening checklist (FDA)
- PAXLOVID drug interactions\\xa0(IDSA)
- Contribute to\\xa0ASTMH fundraiser at PWB
- Dr. Griffin\\u2019s treatment guide (pdf)
- Letters read\\xa0on TWiV 899
- Timestamps by Jolene. Thanks!
Intro music is by\\xa0Ronald Jenkees
Send your questions for Dr. Griffin to daniel@microbe.tv